| Revenue guidance | 5.0% → 9.0% Raised by 4.0 percentage points |
|---|---|
| Management target | Revenue 18.0% FY27 |
| Revenue growth | ₹1,794 Cr, 33% YoY growth driven by US and Africa. |
|---|---|
| Margins | EBITDA margin improved to 30% from 27% YoY. |
| Demand visibility | Strong in Asia/Africa branded markets; US normalizing after one-time gains. |
| Management confidence | Balanced; optimistic on branded generics but cautious on US pricing/competition. |
Growth
Revenue grew 33% YoY; US generics surged 41% due to limited competition in key products.
Outlook
Maintained high-teens revenue growth guidance for FY27; EBITDA margin target 27%.
Risks
US growth to normalize as new competitors enter; Institutional Africa sales unpredictable/non-recurring.
Earnings Call Transcript filed with NSE, NSE: AJANTPHARM. Summary written with AI assistance from the document.
Ajanta Pharma Ltd: key numbers
- Share price
- ₹3,508.80
- Market cap
- ₹43,846 Cr
- Revenue (annual)
- ₹5,453 Cr
- Net profit (annual)
- ₹1,056 Cr
- P/E (TTM)
- 34.7×Sector 45.9×
- Promoter holding
- 63.47%-0.01% QoQ
- FII holding
- 7.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ajanta Pharma Ltd
All →Ajanta Pharma Q2 FY27 Results: Net Profit ₹388.1 Cr, Up 49.2% YoY
Ajanta Pharma Ltd reported revenue from operations of ₹1,794 Cr (+32.5% YoY) and net profit of ₹388.1 Cr (+49.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹388.1 Cr · +49.2% YoY
Ajanta Pharma Share Pledge
Ajanta Pharma promoter Aayush Agrawal (trustee) created a pledge on 30,000 equity shares. The pledge was made as a top-up call due to share price reduction.
Ajanta Pharma Board Meeting Date
Ajanta Pharma has scheduled a Board meeting for 30 October 2026 to consider Q2/H1 2026 unaudited financial results. No material decision has been taken yet.
Ajanta Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Ajanta Pharma Share Pledge
Promoter Aayush Agrawal Trust created pledge on 4,60,000 Ajanta Pharma shares. The pledge secures an NCD issue in favor of CTL Trusteeship Ltd.
Ajanta Pharma Share Pledge
CTL Trusteeship Limited reported a pledge creation on 26,21,067 shares (2.10%) of Ajanta Pharma Limited to secure debentures worth Rs. 3,873 Crore. The shares act as collateral for NCDs issued by Lenexis Foodworks and Inspira Realty.
- Value
- ₹3,873 Cr